This article was originally published in The Gray Sheet
Is beginning clinical trials of its Percutaneous Rotational Thrombectomy (PRT) device in the first quarter of this year under an investigational device exemption approved "at the end of last year," President Alan Levy announced at the Piper Jaffray investment conference. The device incorporates a flexible wire that is rotated at 5,000 revolutions per minute to treat arterial blood clots. The exec also reported that Heart Technology has received approval from FDA to resume clinical trials of its Rotablator atherectomy device for coronary applications and sales of the product for peripheral applications. The firm discontinued distribution of the device following a June recall and subsequently revised its manufacturing procedures in November to address the problem that led to the recall ("The Gray Sheet" Nov. 23, I&W-5).
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.